| Identification | Back Directory | [Name]
Phosphonic acid, [(3-broMo-7-cyano-2-naphthalenyl)difluoroMethyl]- (9CI) | [CAS]
809272-64-8 | [Synonyms]
PTP1B-IN-3
PTP1BIN3,PTP-1B-IN-3,PTP1B IN 3
(3-bromo-7-cyanonaphthalen-2-yl)difluoromethylphosphonic acid
P-[(3-BroMo-7-cyano-2-naphthalenyl)difluoroMethyl]phosphonic Acid
Phosphonic acid, [(3-broMo-7-cyano-2-naphthalenyl)difluoroMethyl]- (9CI)
P-[(3-Bromo-7-cyano-2-naphthalenyl)difluoromethyl]phosphonic Acid Diammonium Salt | [Molecular Formula]
C12H7BrF2NO3P | [MDL Number]
MFCD19443182 | [MOL File]
809272-64-8.mol | [Molecular Weight]
362.063 |
| Chemical Properties | Back Directory | [Melting point ]
>277°C (dec.) | [Boiling point ]
565.7±60.0 °C(Predicted) | [density ]
1.86±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Methanol (Very Slightly, Heated), Water (Slightly) | [form ]
Solid | [pka]
1.35±0.10(Predicted) | [color ]
Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
P-[(3-Bromo-7-cyano-2-naphthalenyl)difluoromethyl]phosphonic Acid is a potent and orally active small molecule PTP1B inhibitor.
| [Definition]
ChEBI: [(3-bromo-7-cyano-2-naphthalenyl)-difluoromethyl]phosphonic acid is a member of naphthalenes. | [in vivo]
In diet-induced obese (DIO) mice, PTP1B-IN-3 (compounds 3g) exhibits dose dependent inhibition (60%, 80% and 100% inhibition at 1, 3 and 10 mg/kg, respectively) of glucose excursion when given orally 2 h before oral glucose challenge with an estimated ED50 of 0.8 mg/kg[1].
In the NDL2 Ptpn1 transgenic mice, PTP1B-IN-3 (compounds 3g; orally; 30 mg/kg for 21 days) shows a significant delay in the onset of tumor development in NDL2 Ptpn1+/+ mice, extending the median tumor free days (T50) from 28 days to 75 days[1].
In diet-induced obese (DIO) mice, PTP1B-IN-3 (compounds 3g) exhibits good oral bioavailability (F of 24%), slow clearance (CL of 0.71 mL/kg/min), and good elimination half live (t1/2 of 6 h). The oral bioavailability in higher species such as rats (F of 4%) and squirrel monkeys (F of 2%) are substantially lower but excellent exposures are achieved with oral dosing[1]. |
|
|